Given that IL17A‐targeted monoclonal antibodies (e.g., secukinumab) are already FDA‐approved for autoimmune diseases with well‐characterised safety profiles, combining such agents with neoantigen or ENO1 vaccines could be rapidly tested in early‐phase PDA trials. This evidence concerns the gene ENO1 and Patent ductus arteriosus.